MEDICAMEN Organics Limited

Regd. & Corporate Office: 10, Community Centre No.2, Ashok Vihar Phase-II, Delhi-110052 (India)
Tel: 011-27430249, 27138171
E-mail: info@mediorganics.in | **CIN No:** L74899DL1995PLC066416 | GSTIN:07AABCM4302P1ZF

Ref. No.: MEDIORG/NSE/2026-27/32

Saturday, November 07, 2026

To,
Listing Compliance Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra-Kurla Complex,
Bandra (E), Mumbai – 400051, India

NSE Symbol: MEDIORG
Company ISIN: INE0PE401018

Subject: **Submission of Certificate from Statutory Auditors in terms of Regulation 169(5) of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018 ("ICDR Regulations")**

Dear Sir/Madam,

Pursuant to Regulation 169(5) of the ICDR Regulations, please find enclosed herewith a certificate issued by M/s. N C Raj & Associates, Chartered Accountants (Firm Registration No.: 002249N) ("**Statutory Auditors**"), certifying that Medicamen Organics Limited ("**Company**") is in compliance with Regulation 169(4) of the ICDR Regulations and that the relevant supporting documents are maintained by the Company.

The said certificate has been obtained in connection with the receipt of balance consideration of INR 87,50,000/- (Indian Rupees Eighty-Seven Lakh Fifty Thousand Only) on November 07, 2026, from Mr. Pradeep Kumar Jain towards exercise of the conversion option attached to 10,00,000 (Ten Lakh) Warrants allotted on a preferential basis on June 09, 2026, and the consequent allotment of 10,00,000 (Ten Lakh) fully paid-up Equity Shares of face value INR 10/- each at an issue price of INR 35/- per Equity Share, including a premium of INR 25/- per Equity Share, on November 07, 2026.

The Company had earlier received INR 2,62,50,000/- (Indian Rupees Two Crore Sixty-Two Lakh Fifty Thousand Only), being 75% of the total consideration, towards the aforesaid Warrants. Accordingly, the entire consideration aggregating to INR 3,50,00,000/- (Indian Rupees Three Crore Fifty Lakh Only) has been received by the Company.

The statement of consideration received is set out in **Annexure 1** to the enclosed certificate.

Kindly take the above on record and acknowledge receipt.

Thanking you,
Yours faithfully,
For Medicamen Organics Limited

Divya Sharma
Digitally signed by Divya Sharma
Date: 2026.11.07 19:05:57 +05'30'

Divya Sharma
Company Secretary & Compliance Officer
Membership No.: A43980
Place: New Delhi

Enclosed: As above

N C RAJ & ASSOCIATES
Chartered Accountants
10, Community Centre No.2,
Ashok Vihar Phase-II,
Delhi – 110 052
Phone: +911149057181
Website: www.ncraj.com
Email: info@ncraj.com
Peer Review No.:021949

Independent Auditor's Certificate on receipt of consideration towards the fully convertible warrants allotted by Medicamen Organics Limited pursuant to the requirement of Regulation 169(5) of Part VI of Chapter V of Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018 (as amended)

To
The Board of Directors
Medicamen Organics Limited
10 Community Centre No. 2,
Ashok Vihar Phase II, New Delhi
110052

1. This certificate is issued in accordance with the terms of our engagement letter dated 08.06.2026 with Medicamen Organics Limited ('the **Company'**).

2. The accompanying Statement (the **'Statement'**) containing details of receipt of consideration towards allotment of fully convertible warrants (the '**specified securities**') and confirming compliance with the requirements of Chapter V of Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended, (the '**ICDR Regulations'**) including Regulation 169(4) of Part VI of Chapter V of the ICDR Regulations, section 42 and 62 of the Companies Act, 2013 (the '**Act'**) and rule 14 of the Companies (Prospectus and Allotment of Securities) Rules, 2014 and rule 13 of the Companies (Share Capital and Debentures) Rules, 2014 (the '**Rules'**) to the extent applicable, in respect of the preferential issue of fully convertible warrants on a private placement basis as approved by the Board of Directors of the Company in its meeting dated March 13, 2026, has been prepared by the Company's management for the purpose of submission along with this certificate to National Stock Exchange of India Limited (referred to as the 'Stock Exchange') pursuant to the requirements of Regulation 169(5) of the ICDR Regulations. We have initialed the Statement for identification purposes only.

Management's Responsibility for the Statement

3. The preparation of the Statement, including the preparation and maintenance of all accounting and other relevant supporting records and documents is solely the responsibility of the management of the Company. This responsibility includes design, implementation,

and maintenance of internal controls relevant to the preparation and presentation of the Statement and applying an appropriate basis of preparation and making estimates that are reasonable in the circumstances.

4. The management is also responsible for:
   a. ensuring that the consideration for the specified securities is received from the respective allottee's bank account;
   b. maintenance of relevant records and documents in relation to point (a) above;
   c. compliance with the requirements of the ICDR Regulations, the Act and the Rules; and
   d. providing all relevant information to Securities and Exchange Board of India (the '**SEBI**') and the stock exchanges.

Auditor's Responsibility

5. Pursuant to the requirements of Regulation 169(5) of Part VI of Chapter V of the ICDR Regulations, it is our responsibility to express limited assurance in the form of a conclusion as to whether anything has come to our attention that causes us to believe that the accompanying Declaration confirming applicability of Regulation 169(4) of the ICDR Regulations with respect to the proposed preferential issue, is not fairly stated.

6. We conducted our examination of the Statement for the purpose of this certificate in accordance with the Guidance Note on Reports or Certificates for Special Purposes (Revised 2016) ('the Guidance Note') issued by the Institute of Chartered Accountants of India ('the ICAI'). The Guidance Note requires that we comply with the ethical requirements of the Code of Ethics issued by the ICAI.

7. We have complied with the relevant applicable requirements of the Standard on Quality Control (SQC) 1, Quality Control for Firms that Perform Audits and Reviews of Historical Financial Information, and Other Assurance and Related Services Engagements, issued by the ICAI.

8. The procedures performed in a limited assurance engagement vary in nature and timing from, and are less in extent than for, a reasonable assurance engagement; and consequently, the level of assurance obtained in a limited assurance engagement is substantially lower than the assurance that would have been obtained had a reasonable assurance engagement been performed. The procedures selected depend on the auditor's judgement, including the assessment of the areas where a material misstatement of the subject matter information is likely to arise. Accordingly, we have performed the following procedures in relation to the accompanying Statement:

   a. Obtained and read the certified copy of the resolution passed at Extra-ordinary General Meeting and the meeting of the Board of Directors held on April 9, 2026 and March 13, 2026 respectively in respect of the preferential issue of the fully convertible warrants.
   b. Obtained bank statement of the allottees as provided by the management and ensured that the consideration has been received from the allottee's bank account. Further, we have only relied on the information obtained from the management in this regard, and have not performed any independent confirmation procedures;

c. Verified the amount of consideration received towards preferential issue with the bank statement of the Company and traced it to the respective receipt date as mentioned in the accompanying Statement; and
d. Conducted relevant management enquiries and obtained necessary representations from the management of the Company.

Conclusion

9. Based on the procedures performed as above, evidences obtained and the information and explanations given to us, along with representations provided by the Management, nothing has come to our attention that causes us to believe that the details included in the accompanying Statement, are, in all material respects, not fairly stated.

Restriction on Distribution or Use

10. Our work was performed solely to assist you in meeting your responsibilities in relation to your compliance with Regulation 169(5) of the ICDR Regulations. Our obligations in respect of this certificate are entirely separate from, and our responsibility and liability is in no way changed by, any other role we may have as statutory auditors of the Company or otherwise. Nothing in this certificate, nor anything said or done in the course of or in connection with the services that are the subject of this certificate, will extend any duty of care we may have in our capacity as statutory auditors of the Company.

11. This certificate is addressed to and provided to the Board of Directors of the Company solely for the purpose of enabling it to comply with the requirements of Regulation 169(5) of the ICDR Regulations, which inter-alia require the Company to submit this certificate along with the accompanying Statement to the stock exchange in connection with the preferential issue of equity shares and convertible warrants and therefore should not be used, referred to or distributed for any other purpose or to any other party without our prior written consent. Accordingly, we do not accept or assume any liability or any duty of care for any other purpose or to any other person to whom this certificate is shown or into whose hands it may come without our prior consent in writing.

For N C Raj & Associates
Chartered Accountants
Firm Registration No.: 002249N

SANJAY GARG
Digitally signed by SANJAY GARG
Date: 2026.11.07 18:44:21 +05'30'

Sanjay Garg
Partner
Membership No.: 088636
UDIN: 26088636CECVIY3980
Place: New Delhi
Date: 07.11.2026

Annexure 1

Medicamen Organics Limited

Statement on consideration received towards issuance of specified securities by Medicamen Organics Limited and confirming compliance with the requirements of Chapter V of the ICDR Regulations including Regulation 169(4) of Part VI of Chapter V of the ICDR Regulations, section 42 and 62 of the Act and the Rules:

Sr No.	Name of allottee	Category	Type of consideration	Type of security	Number of specified securities	Amount of consideration (INR)	Date of receipt of consideration as application money for equity and warrant allotment /loan	Allottee bank name / Recipient bank name
1.	Pradeep Kumar Jain	Non-Promoter (NRI-Individual)	Cash	Fully Convertible Warrants (25% of the warrant value)	10,00,000	87,50,000	07.11.2026	Axis Bank / Axis Bank
				Total	**10,00,000**	**87,50,000**		

We further confirm that the Company is in compliance with the Regulation 169(4) of Part VI of Chapter V of the ICDR Regulations, section 42 and 62 of the Companies Act, 2013 (the '**Act**') and rule 14 of the Companies (Prospectus and Allotment of Securities) Rules, 2014 and rule 13 of the Companies (Share Capital and Debentures) Rules, 2014 (the '**Rules**') to the extent applicable and relevant documents including records of bank account statements of each allottee regarding balance consideration received from their respective bank accounts, are maintained by the Company.

For Medicamen Organics Limited

Ashutosh Gupta
Whole-time Director
DIN: 00039995
Place: New Delhi
Date: 07.11.2026